Literature DB >> 19535093

Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study.

E Scarpellini1, V Giorgio, M Gabrielli, E C Lauritano, A Pantanella, C Fundarò, A Gasbarrini.   

Abstract

OBJECTIVE: To assess the prevalence of small intestinal bacterial overgrowth (SIBO) in children affected by irritable bowel syndrome (IBS). STUDY
DESIGN: Consecutive children affected by IBS according to Rome II criteria (n = 43) were enrolled at the Gemelli Hospital, Catholic University of Rome. The control population (n = 56) consisted of healthy subjects without IBS symptoms, similar to patients for age, sex, and social background. All subjects underwent lactulose/methane breath test (LBT) to assess small intestinal bacterial overgrowth.
RESULTS: The prevalence of abnormal LBT result was significantly higher in patients with IBS (65%, 28/43) with respect to control subjects (7%, 4/56; OR 3.9, 95% CI 7.3-80.1, P < .00001). Patients with abnormal LBT showed a trend toward a worse visual analog scale score with respect to children with IBS without SIBO, but a significant statistical difference was observed only for bloating.
CONCLUSIONS: Results from this study suggest a significant epidemiologic association between SIBO and IBS in childhood. Placebo-controlled interventional studies with antibiotics used to treat bacterial overgrowth are warranted to clarify the real impact of the disease on IBS symptoms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19535093     DOI: 10.1016/j.jpeds.2009.03.033

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  23 in total

1.  Chronic abdominal pain in children is associated with high prevalence of abnormal microbial fermentation.

Authors:  Brynie Slome Collins; Henry C Lin
Journal:  Dig Dis Sci       Date:  2010-01       Impact factor: 3.199

2.  Functional abdominal pain and irritable bowel syndrome in children and adolescents.

Authors:  Eric Chiou; Samuel Nurko
Journal:  Therapy       Date:  2011-05-01

Review 3.  Microbiota and nonalcoholic steatohepatitis.

Authors:  Kento Imajo; Masato Yoneda; Yuji Ogawa; Koichiro Wada; Atsushi Nakajima
Journal:  Semin Immunopathol       Date:  2013-12-14       Impact factor: 9.623

Review 4.  Gastroduodenal "Dysbiosis": a New Clinical Entity.

Authors:  Ayesha Shah; Mark Morrison; Gerald J Holtmann
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

Review 5.  Small intestinal bacterial overgrowth syndrome.

Authors:  Jan Bures; Jiri Cyrany; Darina Kohoutova; Miroslav Förstl; Stanislav Rejchrt; Jaroslav Kvetina; Viktor Vorisek; Marcela Kopacova
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

6.  Lactulose hydrogen breath test and functional symptoms in pediatric patients.

Authors:  Ana María Madrid; Glauben Landskron; Gabriela Klapp; Alvaro Reyes; Carolina Pizarro; Carlos Defilippi
Journal:  Dig Dis Sci       Date:  2012-05       Impact factor: 3.199

Review 7.  Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: the missing link.

Authors:  Uday C Ghoshal; Kok-Ann Gwee
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-17       Impact factor: 46.802

Review 8.  Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors.

Authors:  Cornelia Kiank; Yvette Taché; Muriel Larauche
Journal:  Brain Behav Immun       Date:  2009-08-19       Impact factor: 7.217

9.  Do gut microbial communities differ in pediatric IBS and health?

Authors:  Vijay Shankar; Richard Agans; Benjamin Holmes; Michael Raymer; Oleg Paliy
Journal:  Gut Microbes       Date:  2013-05-02

10.  Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis.

Authors:  Binrui Chen; John Jae-Woo Kim; Yawen Zhang; Lijun Du; Ning Dai
Journal:  J Gastroenterol       Date:  2018-05-14       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.